
Sample Screenshots of Antibody Database as of June 30, 2024





Your account will expire on July 31, 2024.


If you encounter any problems or have questions, please contact us at support@pipelinereview.com


LOGOUT SEARCH EXPORT REPORTS PROJECTS

Projects



ld	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33287	2024-06-20	TSLP Antibody	Thymic stromal lymphopoietin (TSLP) inhibitor	Rec monoclonal antibody	Antibody	Perseus Therapeutics	United States	Dermatology	Prevention of hair loss in cancer	Preclinical	<u>Q</u>
33286	2024-06-20	CD45-ADC	CD45 and toxic payload	Rec monoclonal antibody conjugated to cytotoxic payload	Antibody	Cimeio Therapeutics	United States	Oncology	Hematologic malignancies in combination with CD45-engineered (shielded) hematopoietic stem cells (HSPCs)	Preclinical	e,
33285	2024-06-20	PHN-010	Undisclosed novel target highly overexpressed in a wide range of solid tumors and DNA topoisomerase I inhibitor as cytotoxic payload	Rec monoclonal antibody conjugated conjugated to a novel topoisomerase I inhibitor agent with DAR of 8	Antibody	Pheon Therapeutics	United States	Oncology	Solid tumors	0	Q
33284	2024-06-20	BDC-4182	Claudin 18.2 (CLDN18.2) and toll-like receptor (TLR) 7/8 agonist	Rec humanized monoclonal antibody conjugated to TLR7/8 agonist	Antibody	Bolt Biotherapeutics	United States	Oncology	Solid tumors	0	Q
33283	2024-06-18	TOUR006; TOUR- 006; PF-04236921;	Interleukin-6 (IL-6) antagonist	Rec fully human IgG2 monoclonal antibody	Antibody	Tourmaline Bio (from Pfizer)	United States	Cardiovascular, blood & acute care	Atherosclerotic cardiovascular disease (ASCVD)	II	Q





Export Export

Dear SampleUser,
Your account will expire on July 31, 2024.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

Print




LOGOUT SEARCH EXPORT REPORTS PROJECTS

Search

Clear

Target: All Targets

Technology: All Technologies





Therapeutic Area Metabolism & endocrine Neurology & psychiatry Phase All Phases

Market sBLA

ld	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33260	2024-04-22	BAN2802; BAN-2802	Not disclosed target	Rec monoclonal antibody using BrainTransporter™ technology	Antibody	BioArctic Neuroscience & Eisai	Japan,Sweden	Neurology & psychiatry	Alzheimer's disease	Preclinical	Q
33226	2024-04-08	E2025; E-2025	Erythropoietin- producing hepatocellular receptor A4 (EphA4) antagonist	Rec monoclonal antibody	Antibody	Eisai	Japan	Neurology & psychiatry	Alzheimer's disease (AD)	ı	Q
33211	2024-03-28	CM383; CM-383	Amyloid beta protofibrils	Re cmonoclonal antibody	Antibody	Keymed Biosciences	China	Neurology & psychiatry	Alzheimer's disease	СТА	Q
33200	2024-03-25	SSS40; SSS-40	Nerve growth factor (NGF)	Rec humanized monoclonal antibody	Antibody	3SBio (Shenyang Sunshine Pharmaceuticals)	China	Neurology & psychiatry	Moderate to severe bone metastasis cancer pain	I	•
33178	2024-03-21	MEDI0618; MEDI-0618	Protease-Activated Receptor-2 (PAR2) antagonist	Rec monoclonal antibody	Antibody	AstraZenec	United Kingdom	Neurology & psychiatry	Migraine	I	Q
33153	2024-03-18	Mezagitamab; TAK-079	CD38 (for CD38+ cell depletion)	Rec fully human, non- agonistic IgG1 cytolytic monoclonal antibody. SC	Antibody	Takeda Pharmaceutical Co	Japan	Neurology & psychiatry	Primary immune thrombocytopenia	II	•

W Export **E**xport

Dear SampleUser,
Your account will expire on July 31, 2024.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

Print

LOGOUT SEARCH EXPORT REPORTS PROJECTS

Target: Complement C5 Antibodies: Biosimilars ; ✔

Technology: All Technologies

O Any Word O All Words O Exact Phrase O Advanced Search

Search

Clear



Therapeutic Area	
All Therapeutic Areas	
Cardiovascular, blood & acute care	
Dermatology	-
Phase	
All Phases	_

Market oDI A

						SBL	A				
ld	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
32552	2023-07-30	Soliris; eculizumab; H5G1.1	Complement C5 inhibitor	Rec humanized (hybrid IgG2/4) Fc-modified full mab for intravenous administration	Antibody	AstraZeneca (acquired Alexion Pharmaceuticals)	United Kingdom	Neurology & psychiatry	Refractory generalised myasthenia gravis (gMG) in children and adolescents aged six to 17 years who are antiacetylcholine receptor (AChR) antibodypositive (Ab+)	Market	٩
32523	2023-07-01	Eculizumab (Biocad); BCD-148; eculizumab biosimilar (Russia market)	Complement C5 inhibitor	Rec humanized (hybrid IgG2/4) Fc-modified full mab. Biosimilar of Soliris (Alexion Pharmaceuticals)	Antibody	Biocad	Russian Federation	Cardiovascular, blood & acute care	Atypical hemolytic uremic syndrome (aHUS); paroxysmal nocturnal hemoglobinuria (PNH)	Market	e,
32522	2023-08-19	Veopoz; pozelimab-bbfg; REGN3918; REGN-3918	Complement C5 inhibitor	Rec fully human IgG4 monoclonal antibody (VelocImmune technology), SC and IV	Antibody	Regeneron Pharmaceuticals	United States	Cardiovascular, blood & acute care	Generalized myasthenia gravis (gMG) in combinatoin with cemdisiran after prior pozelimab monotherapy	Ш	Q
32521	2024-01-01	KP104; KP-104 (China study)	Complement factor C5 and factor H (CFH)	Rec bifunctional monoclonal antibody	Antibody	Kira Pharmaceuticals	United States	Cardiovascular, blood & acute care	Paroxysmal nocturnal hemoglobinuria (PNH)	II	Q

Your account will expire on July 31, 2024. If you encounter any problems or have questions, please contact us at support@pipelinereview.com LOGOUT SEARCH EXPORT REPORTS PROJECTS ■ Export
 ■ Export Print Search Territory Search All Countries Aaland Islands Therapeutic Area O Any Word O All Words O Exact Phrase O Advanced Search All Therapeutic Areas Afghanistan Cardiovascular, blood & acute care Albania Target: All Targets Dermatology Algeria American Samoa ~ Technology: ADC - Topoisomerase I Inhibitors Phase Andorra All Technologies All Phases Angola ADC - Auristatin Market ADC - Calicheamicin sBLA ADC - Doxorubicin Id Last ADC - Duocarmycin Indication Phase mpound Category Company Territory Therapeutic Area ADC - Maytansinoid Prevention of hair loss in Preclinical 33287 2024 ADC - Others nal antibody Antibody Perseus Therapeutics United States Dermatology cancer ADC - Proteins & Peptides ADC - Pyrrolobenzodiazepine (PBD) Hematologic ADC - SN-38 (irinotecan metabolite) malignancies in nal antibody ADC - Topoisomerase I Inhibitors combination with CD45-33286 2024 cytotoxic Antibody Cimeio Therapeutics United States Oncology Preclinical Agonist Antibodies engineered (shielded) Bispecific Antibodies hematopoietic stem cells (HSPCs) Bispecific Proteins Camelid-derived Domain Antibodies Cell-Penetrating Antibodies, Proteins and Peptides nal antibody Deimmunized Antibodies onjugated to a 33285 2024 DNA Vaccines merase I Antibody Pheon Therapeutics United States Oncology Solid tumors Fab or di-Fab Construct nt with DAR of Fc-Fusion Protein payload Claudin 18.2 Rec humanized monoclonal (CLDN18.2) and tollantibody conjugated to 33284 2024-06-20 BDC-4182 Antibody **Bolt Biotherapeutics** United States Oncology Solid tumors 0 like receptor (TLR) TLR7/8 agonist 7/8 agonist

